SCYNEXIS (SCYX)
Develops antifungal and rare-disease drug candidates under a GSK licensing model.
$4.54
vs last close−0.32 (−6.58%)
Something off on this page? Send us feedback.
Next report
Nov 4, 26
in 42 days
EPS estimate
−$0.72
Revenue estimate
$147.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.72−$0.88−$1.12−$1.36$2.00−$3.36$0.63Pending
Estimate−$0.02−$1.55−$1.52−$1.60$1.01−$0.80−$0.51−$0.72
Surprise−3,500.0%+43.1%+26.3%+15.0%+98.0%−320.0%+224.3%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$977.0K$257.0K$1.4M$334.0K$18.6M—$235.0KPending
Estimate$10.2M$137.0K$154.0K$133.3K$8.1M$77.0K$80.3K$147.0K
Surprise−90.4%+87.6%+785.7%+150.5%+130.2%—+192.5%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2028 | $0.00 | — | — |
| Sep 2028 | $0.00 | — | — |
| Jun 2028 | $0.00 | — | — |
| Mar 2028 | $0.00 | — | — |
| Dec 2027 | −$1.12 | — | — |
| Sep 2027 | −$1.12 | — | — |
| Jun 2027 | −$1.04 | — | — |
| Mar 2027 | −$0.96 | — | — |
| Dec 2026 | −$0.68 | — | — |
| Nov 2026 | −$0.72 | — | — |
| Aug 2026 | −$0.51 | $0.63 | +224.3% |
| May 2026 | −$0.80 | −$3.36 | −320.0% |
| Mar 2026 | $1.01 | $2.00 | +98.0% |
| Nov 2025 | −$1.60 | −$1.36 | +15.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2028 | $0.00 | — | — | $1.8M | — | — | — |
| Sep 2028 | $0.00 | — | — | $1.7M | — | — | — |
| Jun 2028 | $0.00 | — | — | $1.6M | — | — | — |
| Mar 2028 | $0.00 | — | — | $1.5M | — | — | — |
| Dec 2027 | −$1.12 | — | — | $527.0K | — | — | — |
| Sep 2027 | −$1.12 | — | — | $508.0K | — | — | — |
| Jun 2027 | −$1.04 | — | — | $469.0K | — | — | — |
| Mar 2027 | −$0.96 | — | — | $449.0K | — | — | — |
| Dec 2026 | −$0.68 | — | — | $237.5K | — | — | — |
| Nov 4, 2026 | −$0.72 | — | — | $147.0K | — | — | — |
| Aug 10, 2026 | −$0.51 | $0.63 | +224.3% | $80.3K | $235.0K | +192.5% | −6.2% |
| May 11, 2026 | −$0.80 | −$3.36 | −320.0% | $77.0K | — | — | −10.1% |
| Mar 4, 2026 | $1.01 | $2.00 | +98.0% | $8.1M | $18.6M | +130.2% | +3.2% |
| Nov 5, 2025 | −$1.60 | −$1.36 | +15.0% | $133.3K | $334.0K | +150.5% | −5.5% |
| Aug 14, 2025 | |||||||
| May 16, 2025 | |||||||
| Mar 12, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 29, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 29, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 16, 2021 | |||||||
| May 17, 2021 | |||||||
| Mar 29, 2021 | |||||||
| Nov 6, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 11, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 14, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 8, 2018 | |||||||
| Mar 13, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 13, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Mar 7, 2016 | |||||||
| Nov 13, 2015 | |||||||
| Aug 19, 2015 |